Microbot Medical (NASDAQ:MBOT) Share Price Passes Above 200-Day Moving Average – Time to Sell?

Microbot Medical Inc. (NASDAQ:MBOTGet Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.98 and traded as high as $1.05. Microbot Medical shares last traded at $1.02, with a volume of 426,872 shares.

Microbot Medical Stock Performance

The stock has a market cap of $16.83 million, a PE ratio of -1.26 and a beta of 1.63. The company’s 50-day moving average price is $0.93 and its 200 day moving average price is $0.98.

Microbot Medical (NASDAQ:MBOTGet Free Report) last posted its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17). As a group, equities research analysts predict that Microbot Medical Inc. will post -0.66 earnings per share for the current fiscal year.

Institutional Trading of Microbot Medical

A hedge fund recently bought a new stake in Microbot Medical stock. Thoroughbred Financial Services LLC purchased a new stake in shares of Microbot Medical Inc. (NASDAQ:MBOTFree Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 52,250 shares of the biotechnology company’s stock, valued at approximately $53,000. Thoroughbred Financial Services LLC owned about 0.33% of Microbot Medical at the end of the most recent reporting period. Institutional investors and hedge funds own 16.30% of the company’s stock.

About Microbot Medical

(Get Free Report)

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.

Recommended Stories

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.